Clinical sample quality testing verifies the integrity, purity, stability, and identity of biological specimens before diagnostic or research analysis. Because the pre-analytical phase contributes the majority of laboratory errors, systematic sample quality control is essential for reliable results in clinical diagnostics, biobanking, and molecular testing. This guide outlines tested sample types, core quality indicators, mainstream analytical methods, and practical applications of clinical sample quality testing.
Technical Overview
Clinical sample quality testing is the systematic evaluation of biological specimens to determine whether they meet predefined acceptance criteria before downstream analysis. It covers the entire pre-analytical workflow, including collection, handling, transport, storage, and processing, and assesss parameters such as integrity, purity, concentration, stability, and identity.
Studies consistently show that the pre-analytical phase accounts for approximately 60 to 70 percent of all laboratory errors, far exceeding analytical and post-analytical sources. Compromised specimens can produce falsely elevated or suppressed analyte results, failed molecular assays, non-reproducible research data, and wasted clinical material. Systematic quality testing therefore serves as the first line of defense for result reliability and patient safety.
The practice is governed by international standards and guidelines, including ISO 15189 for medical laboratories, ISO 20387 for biobanks, CLSI documents covering specimen collection and handling, and College of American Pathologists (CAP) accreditation checklists. Together, these frameworks define sample acceptance criteria, rejection limits, testing procedures, and documentation requirements.
Testing Samples
Blood, Serum, and Plasma Specimens
Blood is the most commonly tested clinical specimen. Quality assessment focuses on the hemolysis, icterus, and lipemia (HIL) indices, clotting in anticoagulated tubes, correct tube filling ratios, and the elapsed time between collection and processing. For plasma and serum used in molecular testing, additional checks include cell-free DNA fragment distribution and residual cellular contamination.
Tissue Specimens
Tissue samples, including formalin-fixed paraffin-embedded (FFPE) blocks, fresh-frozen sections, and OCT-embedded specimens, are evaluated for fixation adequacy, cold ischemia time, tissue necrosis, and tumor cellularity. Fixation quality directly determines nucleic acid and protein usability in downstream assays such as next-generation sequencing (NGS) and immunohistochemistry.
Nucleic Acid Extracts
Genomic DNA, total RNA, and circulating cell-free DNA are tested for concentration, purity, and integrity. RNA is particularly labile, and ribosomal RNA integrity is a key predictor of performance in RNA sequencing and gene expression profiling workflows.
Urine, Cerebrospinal Fluid, and Other Body Fluids
These specimens are assessed for visual clarity, bacterial contamination, and preservation status. Protein and metabolite stability, together with the correct use of stabilizing additives, is critical for both routine clinical chemistry and biomarker discovery research.
Cell-Based Samples
Primary cells, peripheral blood mononuclear cells (PBMCs), and cell therapy products are tested for viability, total cell count, phenotype composition, sterility, and endotoxin levels. For advanced therapy medicinal products, these tests constitute mandatory batch release criteria.
Testing Items
Core quality attributes measured in clinical sample quality testing include:
- Physical integrity: hemolysis index, icterus index, lipemia index, clot formation, and volume sufficiency
- Nucleic acid concentration and purity: A260/A280 and A260/A230 ratios and fluorometric quantification
- Nucleic acid integrity: DNA Integrity Number (DIN), RNA Integrity Number (RIN), and DV200 metrics
- Contamination: microbial and mycoplasma contamination, cross-sample contamination, and endotoxin levels
- Cell quality: viability, total nucleated cell count, and phenotype distribution
- Identity and authenticity: STR profiling, SNP-based sample identity verification, and sex-marker concordance
- Stability: time-dependent degradation profiles of proteins, metabolites, and nucleic acids under defined storage conditions
Testing Methods
Spectrophotometry
UV-visible spectrophotometry measures absorbance at 260, 280, and 230 nm to estimate nucleic acid concentration and to flag protein, phenol, and salt contamination through purity ratios. Automated chemistry analyzers apply the same principle to serum and plasma to generate semi-quantitative HIL indices.
Fluorometric Quantification
Dye-based fluorometric assays use nucleic-acid-binding dyes to provide highly specific and sensitive quantification. They are preferred for low-concentration samples such as cell-free DNA, where spectrophotometry tends to overestimate concentration due to co-measured contaminants.
Capillary Electrophoresis
Microfluidic capillary electrophoresis platforms separate nucleic acid fragments by size and generate RIN, DIN, or DV200 scores along with electropherogram-based fragment distribution profiles. These systems are the reference methods for assessing nucleic acid integrity in NGS workflows.
qPCR and Digital PCR
Amplification-based methods quantify amplifiable DNA and RNA, detect PCR inhibitors, and measure fragment size distributions using multiplex assays that target short and long amplicons. Digital PCR adds absolute quantification and high sensitivity for detecting residual DNA and low-level contamination.
Cell Viability and Phenotyping
Trypan blue exclusion assays, flow cytometry with viability dyes, and automated cell counters determine viability and cell count, while immunophenotyping panels verify cell identity and composition in PBMC and cell therapy samples.
Microbiological and Endotoxin Testing
Sterility culture, rapid mycoplasma PCR or enzymatic assays, and Limulus amebocyte lysate (LAL) endotoxin assays verify the biosafety of cell products, primary cultures, and stored specimens.
Molecular Identity Testing
Short tandem repeat (STR) profiling and SNP genotyping confirm sample identity, detect swaps and cross-contamination, and satisfy cell line authentication requirements and molecular laboratory accreditation standards.
Applications
In clinical diagnostics, sample quality testing acts as a gatekeeping step that prevents compromised specimens from generating misleading patient results. Beyond routine laboratories, it underpins several specialized fields:
- Biobanking: ISO 20387-compliant biorepositories test incoming specimens to guarantee long-term fitness for research use and reproducible science
- Clinical trials: central laboratories apply standardized quality control to ensure specimen integrity across multiple sites and support regulatory submissions
- Molecular pathology and NGS: pre-sequencing quality control of nucleic acids reduces library preparation failure rates and unreliable variant calls
- Cell and gene therapy: release testing for viability, identity, sterility, and potency is a strict regulatory requirement
- Transplantation and reproductive medicine: specimen quality directly influences graft assessment and assisted reproduction outcomes
FAQ
What percentage of laboratory errors originate from sample quality problems?
Approximately 60 to 70 percent of total testing errors occur in the pre-analytical phase, with the majority linked to unsuitable specimens. Sample quality testing is therefore one of the most cost-effective quality measures a laboratory can implement.
What is an acceptable RNA Integrity Number?
For most RNA sequencing applications, a RIN of 7 or higher is recommended. For FFPE-derived RNA, where ribosomal peaks are degraded, DV200 (the percentage of RNA fragments longer than 200 nucleotides) is preferred, with values above 30 percent generally acceptable for targeted panels.
Why is fluorometry preferred over spectrophotometry for cell-free DNA?
Spectrophotometry measures total absorbance at 260 nm, including free nucleotides and contaminants, which frequently overestimates cell-free DNA concentration. Fluorometric dyes bind specifically to double-stranded DNA, delivering accurate quantification at the low concentrations typical of cfDNA samples.
How should hemolyzed samples be handled?
Mild hemolysis may be reported with a caution flag depending on the analyte, whereas grossly hemolyzed specimens should be rejected and recollected, because intracellular components released from erythrocytes directly interfere with many chemistry and immunoassay results.
Which standards govern clinical sample quality testing?
Key frameworks include ISO 15189 for medical laboratories, ISO 20387 for biobanks, CLSI specimen collection and handling guidelines, and CAP accreditation checklists, which together define acceptance criteria, testing procedures, and documentation requirements.
